RxDoctor Payments Data

Shakil Ahmed, MD

Interventional Pain Medicine · New York, NYNPI 1962415752

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 61.1% of it on its own, with 3 other manufacturers making up the rest. That places this record below the midpoint for interventional pain medicine clinicians in NY, where the typical reported total is $3,476.

$1,186in general payments, 2019–2025

Across 28 payments — averaging $42.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$725
  • Boston Scientific$340
  • Si-bone, Inc.$97
  • Smith+Nephew$24
$5,562in research payments, 2019–2025

Across 5 payments — averaging $1112.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$6K

What the payments were for

  • Food & beverage$1,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic22$725
Boston Scientific4$340
Si-bone, Inc.1$97
Smith+Nephew1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 30th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$248,602
Medicare patients
423
Services billed
11,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl17$15,747
MovantikNaloxegol Oxalate13$5,736
Lidocaine49$4,612
Gabapentin202$4,341
Fentanyl38$4,265
Buprenorphine11$3,929
Pregabalin74$2,222
Tizanidine Hcl68$2,210
Naproxen21$1,350
Oxycodone Hcl51$970
Baclofen42$884
Diclofenac Sodium44$807
Duloxetine Hcl38$796
Chlorzoxazone22$635
Hydromorphone Hcl37$634

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →